Swine Model Study of Hemorrhagic Shock Demonstrates Efficacy Of Biobeat's Wearable Monitoring Device In Comparison To Invasive Arterial Line And Swan-Ganz Catheter Monitoring Methods

New Peer-Reviewed Study Substantiates Use Of Photoplethysmography-Based (PPG) Device To Help Accurately Monitor Patient Vitals, Even During Significant Hemodynamic Changes

News provided by

Biobeat

Oct 19, 2020, 09:00 ET

PETAH TIKVA, Israel, Oct. 19, 2020 /PRNewswire/ -- Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, announced today the results of a swine model study comparing the hemodynamic parameters during controlled hemorrhagic shock to invasive arterial line (AL) and Swan-Ganz (SG) catheter monitoring methods.

The swine model study, "Wireless, Non-Invasive, Wearable Device for Continuous Remote Monitoring of Hemodynamic Parameters in a Swine Model of Controlled Hemorrhagic Shock," published in Scientific Reports, measured the heart rate, systolic and diastolic blood pressure and cardiac output of 11 pigs using Biobeat's wearable non-invasive remote monitoring device and traditional AL and SG catheter invasive methods. Hemorrhagic shock was induced in the pigs by bleeding 35% of their blood volume, followed by a post-bleeding follow-up phase. The animals were monitored continuously by all three methods for a median period of 447 minutes.

"Accurate and continuous monitoring of critically ill patients is frequently achieved using invasive catheters, which are technically complex and can potentially lead to local injury and infection," said Prof. Arik Eisenkraft, the study's principal investigator and CMO of Biobeat. "During periods of induced hemodynamic instability - in which traditional non-invasive devices often struggle to monitor vitals - Biobeat's PPG-based device succeeded in continuously providing accurate measurements. This provides substantial evidence demonstrating that novel PPG-based devices can also be used for patient monitoring, even when patients experience drastic vital sign variation including significant hemodynamic changes."

Study findings showed unprecedented monitoring capabilities for heart rate, blood pressure, and cardiac output measurements, including hemodynamic deterioration in drastic situations. The overall mean values for the invasive measurement were highly comparable. There also were significant (p<0.001) and strong correlations between methods of measurement of BP during all phases of the study. Correlations between the wearable monitor and the invasive methods were significant (p<0.001) during all periods, and correlations for changes in cardiac output, systolic and diastolic blood pressure were significant (p<0.001) and strong (r>0.88). Notably, the comparison between AL and SG catheters with Biobeat's non-invasive PPG device showed first-of-its-kind accordance in relation to blood pressure and cardiac output. Overall, these findings indicate that a PPG-based device like Biobeat's can be helpful in accurately and continuously tracking changes in patient conditions, even in clinical settings where patients experience notable hemodynamic changes.

"There is a clear need for reliable non-invasive technology capable of advanced hemodynamic monitoring within the medical space," said Arik Ben Ishay, CEO of Biobeat. "Measurements obtained from the study indicated that Biobeat's PPG-based device can offer a high level of reliability compared to existing standard invasive techniques, even in circumstances of moderate to severe and unstable hemorrhagic shock. This further proves that Biobeat's PPG-based monitoring device can provide continuous non-invasive monitoring to support timely care, which may help health teams minimize morbidity and mortality without compromising measurement accuracy."

About Biobeat

Biobeat is a med-tech company with unique health-AI abilities in the patient monitoring space. The company's remote patient monitoring (RPM) health-AI platform includes a disposable short-term chest-monitor and a long-term wrist-monitor, both of which utilize a photoplethysmography-based (PPG) sensor to continuously provide accurate patient readings of 15 health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, temperature, stroke volume, cardiac output, one lead ECG (only chest-monitor) and more. Leveraging its automatic, continuous and noninvasive RPM AI platform, Biobeat has generated the biggest vital-sign database in the world, which it utilizes to identify early deterioration of patients via its proprietary big-data and health-AI tools.

Aggregated patient health data is viewed by medical staff via Biobeat's secure HIPPA and GDPR compliant cloud-based patient management platform, which utilizes an automated real-time early warning score (EWS) system that incorporates advanced AI-based algorithms to provide alerts on patient health status and potential deterioration. These capabilities allow Biobeat to support medical teams with tailored patient care such as adjustment of therapeutics and early prevention of specific disease exacerbations. Biobeat's wearable devices are the first devices to be FDA-Cleared for cuffless non-invasive blood pressure monitoring and are also CE Mark certified. Founded in 2016, Biobeat is headquartered in Petah Tikva, Israel.

For more information, visit: https://www.bio-beat.com.

Follow Biobeat on LinkedIn.

Logo - https://mma.prnewswire.com/media/1091048/Biobeat_Logo.jpg

Media Contact:
Mordy Derovan
Finn Partners
+1 929 222 8012
[email protected]

Company Contact:
Tomer Epstein
[email protected]

SOURCE Biobeat